Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum ß-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
J Antimicrob Chemother
; 69(9): 2448-52, 2014 Sep.
Article
en En
| MEDLINE
| ID: mdl-24827891
ABSTRACT
OBJECTIVES:
We assessed the pharmacodynamic activity of ertapenem against Escherichia coli with reduced susceptibility (MIC 0.12-0.5 mg/L), intermediate resistance (MIC 1.0 mg/L) or resistance (MIC ≥ 2 mg/L) to ertapenem using an in vitro model.METHODS:
Fifteen extended-spectrum ß-lactamase- or carbapenemase-producing E. coli were studied. The in vitro pharmacodynamic model was inoculated with â¼1â×â10(6) cfu/mL and ertapenem was dosed once daily at 0 and 24 h to simulate free (ƒ) Cmax and t½ obtained after either 1 g or 2 g intravenous once-daily doses in healthy volunteers (1 g ƒCmax 15 mg/L, t½ 4 h). Sampling was performed over 48 h to assess viable growth and resistance selection.RESULTS:
An ertapenem T> MIC ≥ 75.4% (ertapenem MICs ≤ 0.5 mg/L) resulted in bactericidal (≥ 3 log10 killing) activity against all strains. An ertapenem T>MIC of 61% was bactericidal at 6 and 12 h but regrowth at 24 and 48 h occurred in some strains. An ertapenem T>MIC of 13%-43% was bactericidal at 6 h but regrowth (with MIC increases) occurred. No inhibition of an NDM strain with an ertapenem T>MIC of 0% (ertapenem MIC 256 mg/L) occurred at any timepoint.CONCLUSIONS:
Once-daily dosing with 1 g of ertapenem was bactericidal against ESBL-producing E. coli with ertapenem MICs ≤ 0.5 mg/L and was bactericidal against strains with MICs of 1.0 mg/L, with regrowth in some strains. Ertapenem MICs of 2-8 mg/L resulted in early bactericidal activity followed by regrowth. Once-daily dosing with 2 g of ertapenem was bactericidal against strains with an MIC of 1.0 mg/L, but regrowth occurred in some strains with an ertapenem MIC of 2 mg/L.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
3_ND
Problema de salud:
3_neglected_diseases
/
3_zoonosis
Asunto principal:
Beta-Lactamasas
/
Resistencia betalactámica
/
Beta-Lactamas
/
Escherichia coli
/
Antibacterianos
Límite:
Humans
Idioma:
En
Revista:
J Antimicrob Chemother
Año:
2014
Tipo del documento:
Article